Nirsevimab Immunisation Significantly Reduces Respiratory Syncytial Virus‐Associated Bronchiolitis Hospitalisations and Alters Seasonal Patterns
Acta Paediatrica · 2025-08 · 114 (8) · 1963-1976
DOI: 10.1111/apa.70066 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Acta Paediatrica, online erschienen am 26.03.2025. Verfasst von Juan Manuel Rius-Peris und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Virgen de la Luz, Cuenca, Spain. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Hospitalization, Antibodies, Monoclonal, Humanized, Bronchiolitis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Aim
This work was performed to assess the impact of nirsevimab immunisation on acute bronchiolitis hospitalisations during nearly the entire 2023–2024 epidemic year.
Methods
An observational, multicentre, prospective study was conducted from 1 September 2021 to 15 June 2024 across 20 hospitals in two Spanish regions. Infants up to 12 months old admitted for acute bronchiolitis were included. Demographic, clinical and microbiological data were analysed across three epidemic years (2021–2022, 2022–2023 and 2023–2024). Statistical analyses were performed to evaluate the effectiveness of nirsevimab in preventing respiratory syncytial virus (RSV)‐associated hospitalisations.
Results
In total, 2656 patients were included. Bronchiolitis hospitalisations significantly declined in the post‐nirsevimab epidemic year compared with previous years. The 2023–2024 season displayed a bimodal distribution, with the first peak dominated by RSV cases and the second by rhinoviruses and metapneumovirus. The proportion of RSV‐associated bronchiolitis hospitalisations decreased by 20%–30%, while rhinovirus‐ and metapneumovirus‐associated bronchiolitis cases increased by 10%–20%. The effectiveness of nirsevimab in preventing RSV‐associated admissions was estimated to be approximately 70%.
Conclusion
Nirsevimab immunisation significantly reduced RSV‐associated bronchiolitis admissions, though an increase in rhinovirus‐ and metapneumovirus‐associated cases was observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Universitario Virgen de la Luz, Cuenca, Spain.
- Research Group in Electronic, Biomedical and Telecommunication Engineering, University of Castilla-La Mancha, Cuenca, Spain.
- Grupo de Investigación en Ingeniería Biomédica, Instituto de Investigación Sanitariade Castilla-La Mancha (IDISCAM), Spain.
- Hospital Universitario de Ciudad Real, Ciudad Real, Spain.
- Hospital Universitario y Politécnico La Fe, Valencia, Spain.
- Hospital Universitario de Guadalajara, Guadalajara, Spain.
ORCID-Profile: Juan Manuel Rius-Peris
Zitieren
APA
Rius-Peris, J. M., Palomo-Atance, E., Muro-Díaz, E., Llorente-Ruiz, C., Murcia-Clemente, L., & Alcaraz, R. (2025). Nirsevimab Immunisation Significantly Reduces Respiratory Syncytial Virus‐Associated Bronchiolitis Hospitalisations and Alters Seasonal Patterns. Acta Paediatrica, 114(8), 1963-1976. https://doi.org/10.1111/apa.70066
Vancouver
Rius-Peris JM, Palomo-Atance E, Muro-Díaz E, Llorente-Ruiz C, Murcia-Clemente L, Alcaraz R. Nirsevimab Immunisation Significantly Reduces Respiratory Syncytial Virus‐Associated Bronchiolitis Hospitalisations and Alters Seasonal Patterns. Acta Paediatrica. 2025;114(8):1963-1976. doi:10.1111/apa.70066
BibTeX
@article{RiusPeris2025,
author = {Rius-Peris, Juan Manuel and Palomo-Atance, Enrique and Muro-Díaz, Eva and Llorente-Ruiz, Cristina and Murcia-Clemente, Laura and Alcaraz, Raúl},
title = {Nirsevimab Immunisation Significantly Reduces Respiratory Syncytial Virus‐Associated Bronchiolitis Hospitalisations and Alters Seasonal Patterns},
journal = {Acta Paediatrica},
year = {2025},
volume = {114},
number = {8},
pages = {1963--1976},
doi = {10.1111/apa.70066}
}
EUVIMED